Status:
COMPLETED
Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart
Lead Sponsor:
University of Calgary
Collaborating Sponsors:
Heart and Stroke Foundation of Canada
Conditions:
Hypertrophic Cardiomyopathy
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine if a drug called atorvastatin will reduce the size and stiffness of the muscle in the left ventricle of the heart.
Detailed Description
Hypertrophic cardiomyopathy (HCM) is a primary disorder of the heart characterized by a thickened, fibrotic myocardium, with or without a dynamic left ventricular outflow tract gradient. It is a commo...
Eligibility Criteria
Inclusion
- 18 years and over with HCM in the absence of another cardiac or systemic disease capable of producing a prespecified wall thickening
Exclusion
- Required use of statin therapy or intolerance
- A clinical diagnosis of hypertension
- Indication for statin therapy for primary or secondary prevention of coronary artery disease
- Current or anticipated indication in ≤ 1 year for implantable cardioverter defibrillators or other metallic devices preventing cardiac magnetic resonance imaging (MRI).
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00317967
Start Date
April 1 2007
End Date
November 1 2010
Last Update
December 9 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Calgary, Faculty of Medicine
Calgary, Alberta, Canada, T2N 4N1